Exemestane: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Exemestane. Educational only — not medical advice.
Labeled uses
AROMASIN is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy. AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
Source: FDA labeling via NIH DailyMed (set f0b31daa…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.